Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Acquired by BML Capital Management LLC

BML Capital Management LLC raised its stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 12.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the company’s stock after acquiring an additional 241,737 shares during the period. Eliem Therapeutics comprises approximately 4.4% of BML Capital Management LLC’s investment portfolio, making the stock its 6th largest holding. BML Capital Management LLC owned 0.08% of Eliem Therapeutics worth $5,886,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Cerity Partners LLC bought a new position in Eliem Therapeutics during the 4th quarter valued at $37,000. Institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Trading Down 3.1 %

Shares of NASDAQ:ELYM opened at $3.75 on Wednesday. The stock’s fifty day simple moving average is $3.00 and its two-hundred day simple moving average is $2.78. Eliem Therapeutics, Inc. has a 1-year low of $2.34 and a 1-year high of $5.19. The stock has a market cap of $103.95 million, a PE ratio of -2.55 and a beta of 0.51.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.